Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp is experiencing robust growth in its plasma and hospital segments, evidenced by increased collection volumes and market share gains, leading to a notable improvement in organic sales for the hospital segment, which grew 4.5% year-over-year. The company has also demonstrated significant operational efficiency, reflected by a 380 basis point increase in gross margin and a 250 basis point rise in operating margin, indicating enhanced profitability. Additionally, Haemonetics is projecting improved free cash flow for FY26, with expectations of $170-210 million, demonstrating strong financial health and operational performance.

Haemonetics Corp experienced a significant decline in organic plasma sales, which fell 10.1% to $125.4 million, indicating ongoing challenges in sustaining growth within this crucial segment. Additionally, the company's overall organic growth slowed to a 1.8% decline in the second quarter of fiscal 2026, down from a modest 0.5% growth in the previous quarter, suggesting a worrying trend in revenue performance. The expectation of continued declines in Interventional Technologies further exacerbates concerns about operating margins and overall earnings, with projections indicating revenue growth slowing into low-single digits, placing the financial outlook below consensus estimates.